CONDENSED INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Income Statement [Abstract]
Net revenues	$ 8,953	$ 4,374	$ 20,704	$ 11,689
Cost of revenues	5,659	2,586	14,306	7,406
Gross profit	3,294	1,788	6,398	4,283
Operating costs and expenses:
Research, development and clinical trials	10,211	9,276	32,903	29,191
Sales and marketing	8,916	5,384	24,137	16,439
General and administrative	8,405	5,033	22,748	15,800
Total operating costs and expenses	27,532	19,693	79,788	61,430
Operating loss	(24,238)	(17,905)	(73,390)	(57,147)
Financial expenses, net	(809)	(53)	(2,277)	(91)
Loss before income tax expense	(25,047)	(17,958)	(75,667)	(57,238)
Income tax expense	976	362	2,986	528
Net loss	$ (26,023)	$ (18,320)	$ (78,653)	$ (57,766)
Basic and diluted net loss per Ordinary share	$ (2.09)	$ (1.45)	$ (6.21)	$ (4.67)
Weighted average number of Ordinary shares used in computing basic and diluted net loss per share	12,431,586	12,594,483	12,666,455	12,377,832